Home The Word Brain My Amedeo FAQ Privacy About   


As of October 2023, Amedeo had
12,263 active subscribers


  Bladder Cancer

  Free Subscription


20.11.2023

1 Aging (Albany NY)
1 Aktuelle Urol
1 Am J Transl Res
2 Ann Med
2 Arch Esp Urol
1 BMC Cancer
1 BMC Urol
1 Cancer Imaging
2 Cancers (Basel)
2 Clin Cancer Res
1 Curr Med Imaging
2 Curr Oncol Rep
1 Eur J Med Res
2 Front Immunol
4 Int J Mol Sci
3 Int J Urol
1 J Biomol Struct Dyn
2 J Clin Med
1 J Endourol
1 JCO Clin Cancer Inform
1 Life Sci
1 Mutat Res
1 Nephron
1 Pathol Res Pract
1 Pol J Pathol
1 Scand J Urol
2 Sci Rep
1 Scott Med J
1 Small
2 Urol Oncol


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Aging (Albany NY)

  1. WANG J, Zuo Z, Yu Z, Chen Z, et al
    Collaborating single-cell and bulk RNA sequencing for comprehensive characterization of the bladder cancer intratumor heterogeneity and prognostic model development for bladder cancer.
    Aging (Albany NY). 2023;15.
    PubMed         Abstract available


    Aktuelle Urol

  2. KLEE M, Roesch MC, Eggers H, Ivanyi P, et al
    Enfortumab vedotin as a salvage option as 5th line therapy for metastatic urothelial bladder cancer.
    Aktuelle Urol. 2023 Nov 14. doi: 10.1055/a-2148-5799.
    PubMed         Abstract available


    Am J Transl Res

  3. HAN X, Zhang T, Ma Q, Chang R, et al
    Gene expression profiles to analyze the anticancer and carcinogenic effects of arsenic in bladder cancer.
    Am J Transl Res. 2023;15:5984-5996.
    PubMed         Abstract available


    Ann Med

  4. LIANG H, Yang Q, Sun H, Xu Y, et al
    The vascular and morphological characteristics of tumors under narrow-band imaging as predictors for the grade and stage of bladder cancer: a prospective and multi-center study.
    Ann Med. 2023;55:2281656.
    PubMed         Abstract available

  5. WANG Y, Song Y, Qin C, Zhang C, et al
    Three versus four cycles of neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and meta-analysis.
    Ann Med. 2023;55:2281654.
    PubMed         Abstract available


    Arch Esp Urol

  6. LI C, Wan Z, Deng Q, Li Z, et al
    Exploring the Shared Gene Signatures and Molecular Mechanisms between Bladder Urothelial Carcinoma and Metabolic Syndrome.
    Arch Esp Urol. 2023;76:605-621.
    PubMed         Abstract available

  7. YU T, Cui X, Liang N, Wu S, et al
    Postoperative Metachronous Metastasis of Bladder Cancer to Penis: A Case Report.
    Arch Esp Urol. 2023;76:622-626.
    PubMed         Abstract available


    BMC Cancer

  8. ROUSSOT N, Fumet JD, Limagne E, Thibaudin M, et al
    A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer.
    BMC Cancer. 2023;23:1080.
    PubMed         Abstract available


    BMC Urol

  9. WAN H, Zhan X, Li X, Chen T, et al
    Assessing the prognostic impact of prostatic urethra involvement and developing a nomogram for T1 stage bladder cancer.
    BMC Urol. 2023;23:182.
    PubMed         Abstract available


    Cancer Imaging

  10. WOO S, Becker AS, Das JP, Ghafoor S, et al
    Evaluating residual tumor after neoadjuvant chemotherapy for muscle-invasive urothelial bladder cancer: diagnostic performance and outcomes using biparametric vs. multiparametric MRI.
    Cancer Imaging. 2023;23:110.
    PubMed         Abstract available


    Cancers (Basel)

  11. GAO Y, Wang X, Luo H, Chen C, et al
    Exosomal Long Non-Coding Ribonucleic Acid Ribonuclease Component of Mitochondrial Ribonucleic Acid Processing Endoribonuclease Is Defined as a Potential Non-Invasive Diagnostic Biomarker for Bladder Cancer and Facilitates Tumorigenesis via the miR-206
    Cancers (Basel). 2023;15:5305.
    PubMed         Abstract available

  12. HUANG N, Peng L, Yang J, Li J, et al
    FAM111B Acts as an Oncogene in Bladder Cancer.
    Cancers (Basel). 2023;15:5122.
    PubMed         Abstract available


    Clin Cancer Res

  13. GUERCIO BJ, Sarfaty M, Teo MY, Ratna N, et al
    Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience.
    Clin Cancer Res. 2023;29:4586-4595.
    PubMed         Abstract available

  14. LERNER SP, McConkey DJ, Tangen CM, Meeks JJ, et al
    Association of Molecular Subtypes with Pathologic Response, PFS and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer.
    Clin Cancer Res. 2023 Nov 15. doi: 10.1158/1078-0432.CCR-23-0602.
    PubMed         Abstract available


    Curr Med Imaging

  15. YILDIZ AK, Oktem C, Keseroglu BB, Kacan T, et al
    A New Scoring System to Differentiate Bladder Cancer from Intravesical Prostatic Protrusion in the Bladder Neck: BCa-IPP Score.
    Curr Med Imaging. 2023 Nov 10. doi: 10.2174/0115734056241577231023064014.
    PubMed         Abstract available


    Curr Oncol Rep

  16. SANTINI D, Banna GL, Buti S, Isella L, et al
    Navigating the Rapidly Evolving Advanced Urothelial Carcinoma Treatment Landscape: Insights from Italian Experts.
    Curr Oncol Rep. 2023;25:1345-1362.
    PubMed         Abstract available

  17. DLUBAK A, Karwacki J, Logon K, Tomecka P, et al
    Lymph Node Dissection in Upper Tract Urothelial Carcinoma: Current Status and Future Perspectives.
    Curr Oncol Rep. 2023;25:1327-1344.
    PubMed         Abstract available


    Eur J Med Res

  18. CAO P, Chen M, Zhang T, Zheng Q, et al
    A sialyltransferases-related gene signature serves as a potential predictor of prognosis and therapeutic response for bladder cancer.
    Eur J Med Res. 2023;28:515.
    PubMed         Abstract available


    Front Immunol

  19. SHEN C, Chai W, Han J, Zhang Z, et al
    Identification and validation of a dysregulated TME-related gene signature for predicting prognosis, and immunological properties in bladder cancer.
    Front Immunol. 2023;14:1213947.
    PubMed         Abstract available

  20. ZHOU G, Qin G, Zhang Z, Zhao H, et al
    Identification of tryptophan metabolism- and immune-related genes signature and prediction of immune infiltration landscape in bladder urothelial carcinoma.
    Front Immunol. 2023;14:1283792.
    PubMed         Abstract available


    Int J Mol Sci

  21. GARCIA-VALLICROSA C, Falcon-Perez JM, Royo F
    The Role of Longevity Assurance Homolog 2/Ceramide Synthase 2 in Bladder Cancer.
    Int J Mol Sci. 2023;24:15668.
    PubMed         Abstract available

  22. ALSOFYANI AA, Nedjadi T
    Gelsolin, an Actin-Binding Protein: Bioinformatic Analysis and Functional Significance in Urothelial Bladder Carcinoma.
    Int J Mol Sci. 2023;24:15763.
    PubMed         Abstract available

  23. RUIZ DE PORRAS V, Font A
    Molecular Mechanisms of Tumor Progression and New Therapeutic Strategies for Urological Cancers.
    Int J Mol Sci. 2023;24:15795.
    PubMed         Abstract available

  24. XIAO LY, Su YL, Huang SY, Chen YH, et al
    Chitinase 3-like-1 Expression in the Microenvironment Is Associated with Neutrophil Infiltration in Bladder Cancer.
    Int J Mol Sci. 2023;24:15990.
    PubMed         Abstract available


    Int J Urol

  25. TOMIYAMA E, Fujita K, Hashimoto M, Uemura H, et al
    Urinary markers for bladder cancer diagnosis: A review of current status and future challenges.
    Int J Urol. 2023 Nov 15. doi: 10.1111/iju.15338.
    PubMed         Abstract available

  26. ROSAZZA M, Soria F, Gontero P
    Editorial comment-Risk stratification and management of nonmuscle-invasive bladder cancer: A physician survey in six Asia-Pacific territories.
    Int J Urol. 2023 Nov 15. doi: 10.1111/iju.15340.
    PubMed        

  27. NUNES FM, Apolonio JD, Mota-Pinto A, Leao R, et al
    Epigenetic alterations in urothelial bladder cancer associated with disease outcomes.
    Int J Urol. 2023 Nov 14. doi: 10.1111/iju.15335.
    PubMed         Abstract available


    J Biomol Struct Dyn

  28. LIU T, Tang Q, Shan Q, Wang Z, et al
    Identification of potential phytochemical for the inhibition of non-muscle invasive bladder cancer (NMIBC).
    J Biomol Struct Dyn. 2023 Nov 14:1-9. doi: 10.1080/07391102.2023.2280914.
    PubMed         Abstract available


    J Clin Med

  29. D'ANDREA VD, Melnick K, Yim K, Ernandez J, et al
    Evidence-Based Analysis of the Critical Steps of Radical Cystectomy for Bladder Cancer.
    J Clin Med. 2023;12:6845.
    PubMed         Abstract available

  30. STROBACH D, Haimerl L, Mannell H, Stief CG, et al
    The Characterization of Non-oncologic Chronic Drug Therapy in Bladder Cancer Patients and the Impact on Recurrence-Free and Cancer-Specific Survival: A Prospective Study.
    J Clin Med. 2023;12:6749.
    PubMed         Abstract available


    J Endourol

  31. RICH JM, Tillu N, Grauer R, Busby D, et al
    Robot-Assisted Repair of Ureteroenteric Strictures After Cystectomy with Urinary Diversion: Technique Description and Outcomes from the European Robotic Urology Section Scientific Working Group.
    J Endourol. 2023;37:1209-1215.
    PubMed         Abstract available


    JCO Clin Cancer Inform

  32. EMINAGA O, Lee TJ, Laurie M, Ge TJ, et al
    Efficient Augmented Intelligence Framework for Bladder Lesion Detection.
    JCO Clin Cancer Inform. 2023;7:e2300031.
    PubMed         Abstract available


    Life Sci

  33. WANG J, Li X, Chen S, Cao J, et al
    Identification of the role of MCM6 in bladder cancer prognosis, immunotherapy response, and in vitro experimental investigation using multi-omics analysis.
    Life Sci. 2023;335:122253.
    PubMed         Abstract available


    Mutat Res

  34. WU B, Zhou X
    LncRNA UCA1 could regulate the progression of neuropathic pain by regulating miR-135a-5p.
    Mutat Res. 2023;827:111833.
    PubMed         Abstract available


    Nephron

  35. IWASAKI S, Takahashi K, Katano H, Suzuki T, et al
    BK Polyomavirus-Associated Urothelial Carcinoma of the Bladder with a Background of BK Polyomavirus Nephropathy in a Kidney Transplant Recipient.
    Nephron. 2023;147 Suppl 1:53-60.
    PubMed         Abstract available


    Pathol Res Pract

  36. KIM JM, Choi E, Sung SH, Kang H, et al
    Invasive urothelial carcinoma with chordoid features or abundant myxoid stroma: A reappraisal of morphologic spectrum and risk stratification based on molecular classification.
    Pathol Res Pract. 2023;251:154839.
    PubMed         Abstract available


    Pol J Pathol

  37. SUNGU N, Kiran MM
    Status of PD-1 and PD-L1 expression in invasive urothelial carcinoma of the bladder with mismatch repair protein deficiency.
    Pol J Pathol. 2023;74:161-170.
    PubMed         Abstract available


    Scand J Urol

  38. MOLLER CT, Tafjord G, Blindheim A, Berge V, et al
    Initial management and survival of patients with primary metastatic bladder cancer before the immunotherapy era: a population-based study from Norway.
    Scand J Urol. 2023;58:101-108.
    PubMed         Abstract available


    Sci Rep

  39. STRAUB M, Auderset A, de Leval L, Piazzon N, et al
    Nitrogen isotopic composition as a gauge of tumor cell anabolism-to-catabolism ratio.
    Sci Rep. 2023;13:19796.
    PubMed         Abstract available

  40. LI Y, Liu Y, Kang Z, Guo J, et al
    Tumor microenvironment heterogeneity in bladder cancer identifies biologically distinct subtypes predicting prognosis and anti-PD-L1 responses.
    Sci Rep. 2023;13:19563.
    PubMed         Abstract available


    Scott Med J

  41. KRISHNAN J, Symington A, Kernohan N, Bray S, et al
    HMG co-reductase expression and response to intravesical Bacillus Calmette-Guerin in patients with high grade non-muscle invasive urinary bladder cancer receiving statins.
    Scott Med J. 2023 Nov 13:369330231213935. doi: 10.1177/00369330231213935.
    PubMed         Abstract available


    Small

  42. GUO P, Dai P, Yang S, Wang Z, et al
    Engineered Macrophages Tune Intratumoral Cytokines through Precisely Controlled Self-Pyroptosis to Enhance Bladder Cancer Immunotherapy.
    Small. 2023 Nov 14:e2306699. doi: 10.1002/smll.202306699.
    PubMed         Abstract available


    Urol Oncol

  43. BEDKE J, Black PC, Szabados B, Guerrero-Ramos F, et al
    Optimizing outcomes for high-risk, non-muscle-invasive bladder cancer: The evolving role of PD-(L)1 inhibition.
    Urol Oncol. 2023 Nov 13:S1078-1439(23)00342.
    PubMed         Abstract available

  44. SODAGUM L, Passarelli R, Pfail J, Patel HV, et al
    Pelvic lymphadenectomy: Evaluating nodal stage migration and will rogers effect in bladder cancer.
    Urol Oncol. 2023 Nov 10:S1078-1439(23)00324.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.